TapewireFind a company

person · Reporting owner

WILLIAMS KRISTEN

Disclosed activity across 1 company

Tapewire entity
40880
SEC CIK
0001296965

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Pacira BioSciences, Inc.PCRX · Entity 4928Chief Administrative OfficerJune 03, 2026June 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Pacira BioSciences, Inc.

Report date June 03, 2026 · Filed June 05, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect167,062 Ending reported balance After 2026-06-04 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-06-03 · Tax withholding · Disposed 8,528 · Balance 177,321

F1: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

Row 2 · 2026-06-04 · Sale · Disposed 10,259 · Balance 167,062

F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on September 10, 2025.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.

F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on September 10, 2025.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
January 18, 2022 Filed Jan 21, 2022 00:24 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 1,375 $0.00 Strike: $44.20 $0.00
Disclosure

SEC source: 0001209191-22-004202 · doc4.xml · derivative · entry 9

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,375 shares

Expires 2027-06-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date.

Read SEC document
January 18, 2022 Filed Jan 21, 2022 00:24 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 400 $66.14 $26,456.00
Disclosure

SEC source: 0001209191-22-004202 · doc4.xml · nonDerivative · entry 6

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,268

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.07 to $66.27, inclusive.

Read SEC document
January 18, 2022 Filed Jan 21, 2022 00:24 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 23,040 $65.24 $1,503,129.60
Disclosure

SEC source: 0001209191-22-004202 · doc4.xml · nonDerivative · entry 5

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,668

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.02 to $65.95, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 4.

Read SEC document
January 18, 2022 Filed Jan 21, 2022 00:24 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 13,127 $47.65 $625,501.55
Disclosure

SEC source: 0001209191-22-004202 · doc4.xml · nonDerivative · entry 4

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,708

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
January 18, 2022 Filed Jan 21, 2022 00:24 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 6,338 $43.54 $275,956.52
Disclosure

SEC source: 0001209191-22-004202 · doc4.xml · nonDerivative · entry 3

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,581

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
January 18, 2022 Filed Jan 21, 2022 00:24 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 2,600 $38.35 $99,710.00
Disclosure

SEC source: 0001209191-22-004202 · doc4.xml · nonDerivative · entry 2

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,243

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
January 18, 2022 Filed Jan 21, 2022 00:24 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 1,375 $44.20 $60,775.00
Disclosure

SEC source: 0001209191-22-004202 · doc4.xml · nonDerivative · entry 1

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,643

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
June 10, 2021 Filed Jun 12, 2021 00:38 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 847 $60.57 $51,302.79
Disclosure

SEC source: 0001209191-21-040090 · doc4.xml · nonDerivative · entry 3

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,268

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.20 to $60.92, inclusive.

Read SEC document
June 10, 2021 Filed Jun 12, 2021 00:38 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 4,842 $59.43 $287,760.06
Disclosure

SEC source: 0001209191-21-040090 · doc4.xml · nonDerivative · entry 2

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,115

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.03 to $59.99, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 and 4.

Read SEC document
June 09, 2021 Filed Jun 12, 2021 00:38 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 GrantStock Option (Right to Buy) · Derivative 17,500 $0.00 Strike: $60.96 $0.00
Disclosure

SEC source: 0001209191-21-040090 · doc4.xml · derivative · entry 4

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2031-06-09

F5 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
June 09, 2021 Filed Jun 12, 2021 00:38 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 GrantCommon Stock 7,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-040090 · doc4.xml · nonDerivative · entry 1

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,957

F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2022, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Read SEC document
June 04, 2021 Filed Jun 8, 2021 20:20 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 3,930 $61.04 $239,875.41
Disclosure

SEC source: 0001209191-21-038901 · doc4.xml · nonDerivative · entry 1

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,957

F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.

Read SEC document
April 13, 2021 Filed Apr 16, 2021 00:35 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 6,339 $0.00 Strike: $43.54 $0.00
Disclosure

SEC source: 0001209191-21-026889 · doc4.xml · derivative · entry 10

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,010

Underlying: Common Stock · 6,339 shares

Expires 2029-06-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
April 13, 2021 Filed Apr 16, 2021 00:35 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 8,859 $0.00 Strike: $38.35 $0.00
Disclosure

SEC source: 0001209191-21-026889 · doc4.xml · derivative · entry 9

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,765

Underlying: Common Stock · 8,859 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
April 13, 2021 Filed Apr 16, 2021 00:35 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 4,125 $0.00 Strike: $44.20 $0.00
Disclosure

SEC source: 0001209191-21-026889 · doc4.xml · derivative · entry 8

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,375

Underlying: Common Stock · 4,125 shares

Expires 2027-06-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date.

Read SEC document
April 13, 2021 Filed Apr 16, 2021 00:35 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 2,500 $0.00 Strike: $32.35 $0.00
Disclosure

SEC source: 0001209191-21-026889 · doc4.xml · derivative · entry 7

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,500 shares

Expires 2026-12-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date.

Read SEC document
April 13, 2021 Filed Apr 16, 2021 00:35 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 7,030 $68.11 $478,813.30
Disclosure

SEC source: 0001209191-21-026889 · doc4.xml · nonDerivative · entry 6

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,887

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.96 to $68.41, inclusive.

Read SEC document
April 13, 2021 Filed Apr 16, 2021 00:35 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 14,793 $66.40 $982,255.20
Disclosure

SEC source: 0001209191-21-026889 · doc4.xml · nonDerivative · entry 5

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,917

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.96 to $67.95, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3.

Read SEC document
April 13, 2021 Filed Apr 16, 2021 00:35 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 6,339 $43.54 $276,000.06
Disclosure

SEC source: 0001209191-21-026889 · doc4.xml · nonDerivative · entry 4

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,710

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
April 13, 2021 Filed Apr 16, 2021 00:35 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 8,859 $38.35 $339,742.65
Disclosure

SEC source: 0001209191-21-026889 · doc4.xml · nonDerivative · entry 3

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,371

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
April 13, 2021 Filed Apr 16, 2021 00:35 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 4,125 $44.20 $182,325.00
Disclosure

SEC source: 0001209191-21-026889 · doc4.xml · nonDerivative · entry 2

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,512

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
April 13, 2021 Filed Apr 16, 2021 00:35 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 2,500 $32.35 $80,875.00
Disclosure

SEC source: 0001209191-21-026889 · doc4.xml · nonDerivative · entry 1

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,387

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
September 17, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 2,819 $0.00 Strike: $43.54 $0.00
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 36

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,349

Underlying: Common Stock · 2,819 shares

Expires 2029-06-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
September 17, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 7,878 $0.00 Strike: $38.35 $0.00
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 35

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,624

Underlying: Common Stock · 7,878 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
September 17, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 5,502 $0.00 Strike: $44.20 $0.00
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 34

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,500

Underlying: Common Stock · 5,502 shares

Expires 2027-06-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date.

Read SEC document
September 17, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 5,836 $0.00 Strike: $32.35 $0.00
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 33

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500

Underlying: Common Stock · 5,836 shares

Expires 2026-12-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date.

Read SEC document
September 17, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 5,836 $0.00 Strike: $40.34 $0.00
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 32

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,836 shares

Expires 2026-06-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date.

Read SEC document
September 17, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 3,200 $60.22 $192,704.00
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 21

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,887

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.130 to $60.370, inclusive.

Read SEC document
September 17, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 24,671 $59.77 $1,474,585.67
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 20

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,087

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.130 to $60.120, inclusive.

Read SEC document
September 17, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 2,819 $43.54 $122,739.26
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 19

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,758

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
September 17, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 7,878 $38.35 $302,121.30
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 18

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,939

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
September 17, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 5,502 $44.20 $243,188.40
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 17

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,061

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
September 17, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 5,836 $32.35 $188,794.60
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 16

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,559

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
September 17, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 5,836 $40.34 $235,424.24
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 15

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,723

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
September 16, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 2,816 $0.00 Strike: $43.54 $0.00
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 31

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,168

Underlying: Common Stock · 2,816 shares

Expires 2029-06-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
September 16, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 7,874 $0.00 Strike: $38.35 $0.00
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 30

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,502

Underlying: Common Stock · 7,874 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
September 16, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 5,499 $0.00 Strike: $44.20 $0.00
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 29

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,002

Underlying: Common Stock · 5,499 shares

Expires 2027-06-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date.

Read SEC document
September 16, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 5,832 $0.00 Strike: $32.35 $0.00
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 28

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,336

Underlying: Common Stock · 5,832 shares

Expires 2026-12-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date.

Read SEC document
September 16, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 5,832 $0.00 Strike: $40.34 $0.00
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 27

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,836

Underlying: Common Stock · 5,832 shares

Expires 2026-06-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date.

Read SEC document
September 16, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 21,244 $60.33 $1,281,650.52
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 14

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,887

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.005 to $60.915, inclusive.

Read SEC document
September 16, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 SaleCommon Stock 6,609 $59.54 $393,499.86
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 13

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,131

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.990 to $59.980, inclusive.

Read SEC document
September 16, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 2,816 $43.54 $122,608.64
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 12

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,740

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
September 16, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 7,874 $38.35 $301,967.90
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 11

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,924

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
September 16, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 5,499 $44.20 $243,055.80
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 10

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,050

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
September 16, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 5,832 $32.35 $188,665.20
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 9

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,551

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
September 16, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionCommon Stock 5,832 $40.34 $235,262.88
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 8

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,719

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Read SEC document
September 15, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 2,816 $0.00 Strike: $43.54 $0.00
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 26

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,984

Underlying: Common Stock · 2,816 shares

Expires 2029-06-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
September 15, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 7,874 $0.00 Strike: $38.35 $0.00
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 25

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,376

Underlying: Common Stock · 7,874 shares

Expires 2028-06-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Read SEC document
September 15, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 5,499 $0.00 Strike: $44.20 $0.00
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 24

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,501

Underlying: Common Stock · 5,499 shares

Expires 2027-06-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date.

Read SEC document
September 15, 2020 Filed Sep 17, 2020 23:13 UTC Pacira BioSciences, Inc. PCRX · Entity 4928 Exercise / conversionStock Option (Right to Buy) · Derivative 5,832 $0.00 Strike: $32.35 $0.00
Disclosure

SEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 23

Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,168

Underlying: Common Stock · 5,832 shares

Expires 2026-12-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.